509 related articles for article (PubMed ID: 32457038)
1. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
2. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Brufsky A
J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
[TBL] [Abstract][Full Text] [Related]
6. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
9. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
10. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
12. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
13. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
15. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
17. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
Poduri R; Joshi G; Jagadeesh G
Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
19. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
20. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.
Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J
APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]